We're relentlessly pursuing novel solutions to save lives and improve health.
We are **AbbVie**, a highly focused, research-driven biopharmaceutical company.

With approximately 30,000 employees around the world, we are dedicated to developing and delivering a consistent stream of innovative new medicines.

We are a passionate, diverse and inclusive organization with a culture that supports the best ideas, wherever they originate. Our scientists are shaping their fields and inspire us to do all we can to bring medicines to patients quickly and safely.

With a focus on leadership, development and performance, we are proud to have been recognized around the world as a great place to work and a top science employer.

We believe that impact goes beyond medicine, which is why we also provide broader support to our patients, operate responsibly and actively give back to the communities where we live and work.

With leading scientific and industry capabilities, a comprehensive approach to tackling the toughest health care challenges and a track record of achievement, we are in pursuit of better health outcomes.

This report highlights the impact of our efforts in 2018.

---

**Our Focus**

At AbbVie, we strive to make a remarkable impact on the lives of patients. We do this by focusing on these therapeutic areas:

- Immunology
- Oncology
- Neuroscience
- Virology
- Women's health
In more than 70 countries, AbbVie employees are working every day to advance health solutions for people around the world.

~30k employees globally

14 manufacturing facilities

175+ countries where products are sold

8 research & development centers

Through the work that we do, AbbVie has been recognized by organizations around the world in addition to more than 40 great workplace and diversity and inclusion lists.

**Workplace & Diversity**
- FORTUNE 100 Best Companies to Work For
- DiversityInc.
- Corporate Equality Index
- Science Magazine’s Top Employers
- World’s Best Workplaces
- Working Mother 100 Best Companies

**Corporate Responsibility**
- Dow Jones Sustainability World Index
- FTSE4Good Index
- Civic 50
- Best Workplaces for Giving Back

**Business Performance**
- Pharma Reptrak Most Reputable Companies
- FORTUNE World’s Most Admired Companies
- FORTUNE 500
Impact on patients

We tackle areas of greatest need today, and prepare for those of the future

We leverage more than 125 years of innovation with therapies in 32 diseases, while continuing to invest in the discovery and development of new medicines for a healthier world.

30m+
patients treated by AbbVie’s medicines every year

We're studying compounds that have potential to treat

1.5b+
people globally including

160m+
potential patients that live in the U.S.
AbbVie is committed to understanding the patient experience across countries and conditions to reduce barriers to treatment and avoidable health care spending.

175+ countries where our products help patients

32 conditions treated across infant, adolescent, adult and senior stages of life

Helping patients through our support programs

2.3m patient impacts through 292 AbbVie patient support programs globally

1.6m patient impacts through 90 support programs in the U.S.

~81,000 U.S. patients received medicine at no cost in 2018 through patient assistance programs

We support independent education programs for patients, caregivers and health care providers.

609,980 health care professionals reached through independent medical education grants

545,130 patients reached through independent patient education grants

Partnering to support neonatology globally

AbbVie supports Good to Grow (G2G) efforts in more than 20 countries. G2G was co-created in 2009 with aims to improve the standards of prevention, care and support for infants born premature and their caregivers, “giving every baby born premature the best possible start in life.”

Worldwide one in 10 babies are born prematurely every year impacting 15 million babies per year.¹ With stakeholders, the initiative is shaping local health care systems to deliver the best possible services and care for every premature infant.

Impact on science

Science and innovation are cornerstones of our business. We focus on discovering, developing and delivering medicines where we have proven expertise and can bring greater benefits to patients.

Investment

$5.1b* to advance science

80% of R&D dollars are invested in the U.S.

It takes unwavering commitment and confidence to bring solutions from the petri dish to patients. AbbVie invested $5.1 billion in research and development (R&D) in 2018 to discover and test compounds with the potential to treat more than 1.5 billion people across the globe. We continue to invest in areas with significant unmet medical need.

*$5.1 billion R&D spend (excluding specified items)

Advancing scientific knowledge every day

Our scientists in the medical research community published 1,130 papers in 2018—allowing others to build on scientific knowledge we developed. We’re also constantly looking for great ideas outside our own walls. More information is available at www.openinnovation.abbvie.com.

We take smart risks when the stakes are high

We are courageous in the face of tough decisions, and learn from failures that are inevitable in the scientific process. Consistent with our long-term strategy and large investment in R&D, we have a number of programs in mid- and late-stage development and continue to make significant pipeline advancements.
AbbVie has a robust pipeline

200+ oncology clinical trials in 20 different types of cancers

51 potential new medicines or new indications for existing medicines in oncology clinical trials

22 state-of-the-art R&D and manufacturing centers

Clinical trials participation

104k+ patients globally

40k+ patients in the U.S.

71 countries

Driving innovation, together

AbbVie partners with more than 220 leading biotechs, universities, non-profits, and government organizations to collaborate and advance science every year.

AbbVie’s discovery and development is driven by leading scientists and workspaces. IDEA Pharma’s Productive Innovation Index ranked AbbVie number 5 among the top pharmaceutical companies most successful at developing and commercializing new medicines.²

New molecular entities (NMEs)

4 NME indications advanced to Phase 3

3 NME indications advanced to Phase 2 with registration potential

11 key programs registration submissions

9 new product or indication approvals including indication expansions

Our talented employees

More than 1/8 of AbbVie employees globally have a doctoral degree in comparison to 1/25 of the U.S. general employee population.³

~9,000 working in science globally

5,300+ working in science in the U.S.

72% of compounds in clinical development including P2 with regulatory potential, P3 or 3B, have a novel mechanism of action, which is considered "first-in-kind" in the scientific community.


2018 was a significant year in our efforts to build long-term community strength. AbbVie made $350 million in charitable contributions to support U.S. non-profits in addition to our ongoing support for education and community programs, independent medical and patient education, and employee vitality and volunteerism.

**Impact on Societies**

<table>
<thead>
<tr>
<th>Organization</th>
<th>Impact Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ronald McDonald House Charities</td>
<td>will add 600 new guest sleeping rooms and family-centered spaces in 32 locations</td>
</tr>
<tr>
<td>St. Jude Children’s Research Hospital</td>
<td>will serve 8,500 patients each year in the new Family Commons space and add 6.5 new acres of green space</td>
</tr>
<tr>
<td>Family Reach</td>
<td>will expand and accelerate its programs and reach 25 new hospitals in 23 states</td>
</tr>
<tr>
<td>Habitat for Humanity</td>
<td>expects to directly assist 13,000 hurricane-affected residents in Puerto Rico</td>
</tr>
<tr>
<td>Direct Relief</td>
<td>will support 60 community health centers in Puerto Rico</td>
</tr>
<tr>
<td>Communities In Schools</td>
<td>will increase reach to 143 schools and serve 100,000 more at-risk kids</td>
</tr>
<tr>
<td>City Year</td>
<td>will expand in Chicago to reach schools that serve 18,000 students</td>
</tr>
<tr>
<td>University of Chicago Education Lab</td>
<td>will generate evidence to guide policy in Chicago and cities nationwide</td>
</tr>
</tbody>
</table>
**AbbVie Gives Back**

**AbbVie’s signature volunteer initiative—Week of Possibilities**

56 countries participated in Week of Possibilities  
9k volunteers  
37k volunteer hours in a single week  
93k hours in 2018

**AbbVie volunteers expertise to combat neglected diseases**

An estimated one billion people suffer from neglected tropical diseases. In response, more than 400 of AbbVie’s most experienced scientists voluntarily contribute expertise to partner organizations and help advance the discovery and development of new medicines for onchocerciasis (river blindness), lymphatic filariasis (elephantiasis), malaria and tuberculosis. Since 2013 AbbVie scientists have dedicated 130,000 pro-bono hours to researching neglected diseases.

500k+ books donated to students in the U.S. by the AbbVie Foundation.

**SEEK: Nurturing young scientists**

Science Engineering Exploration Knowledge (SEEK) is a program focused on lighting a spark in science, technology, engineering and math (STEM) for students in underserved communities through hands-on experience—often involving life-science pros.

In 2018, AbbVie employees around the world volunteered 1,650 hours to support the program, offering 1,860 students hands-on insight into the scientific discovery process.

13k+ health care workers educated or trained since 2013

**The AbbVie Foundation**

The AbbVie Foundation is a non-profit 501(c)3 entity. It is dedicated to having a remarkable impact on the lives of the underserved around the world through a commitment to building strong communities, sustainable health care systems and effective educational programs.
We value the diverse backgrounds and perspectives of our employees, and we have an inclusive culture. AbbVie is also committed to recruit, engage and support U.S. troops and veterans as they re-enter civilian life.

AbbVie is an economic multiplier. With approximately 30,000 employees globally, our total impact on employment is more than five times that amount through direct and indirect business activity.⁴

Each job at AbbVie creates opportunity for others

The jobs we create pay well and attract a workforce with diverse skills and education—including Ph.D. research scientists, laboratory technicians, support staff and more—who live, work and spend money in their local communities. We also spend millions of dollars each year with suppliers purchasing goods and services. This all provides benefits for third-party suppliers and local economies in the form of higher sales, tax revenue and economic development.

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>53%</strong> female share of our total workforce</td>
<td><strong>47%</strong> females in management</td>
</tr>
<tr>
<td><strong>53%</strong> female new hires</td>
<td><strong>31%</strong> under represented populations in our</td>
</tr>
<tr>
<td></td>
<td>workforce (U.S.)</td>
</tr>
</tbody>
</table>

In 2018, AbbVie spent more than $13.3 billion with more than 51,000 third-party suppliers across 606 industries. AbbVie creates opportunities and growth to support the discovery, development and distribution of new medicines. This investment includes diverse suppliers: AbbVie spent nearly $900 million with more than 2,000 U.S. small and diverse-owned businesses in 2018.

AbbVie creates jobs & stimulates economic activity

136 countries with suppliers

50 states with suppliers plus Washington, DC

$8.8b spent with third parties in the U.S.

AbbVie has a presence in all 50 states

Largest states:

- ~1.7k employees in California
- ~9.3k employees in Illinois
- ~1k employees in Massachusetts

- ~1.2k employees in Puerto Rico
- ~2.8k employees in Germany
- ~1.3k employees in Italy
- ~1.2k employees in Japan